SCHEMBL26105147

SCHEMBL26105147

CCn1ccc2c(C=O)cc(Cl)nc21

nearest known ligand 0.32

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP19A1 P11511 1/20 0.32
▸ PTGER4 P35408 2/20 0.32
▸ KDM4E B2RXH2 2/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ HIF1A Q16665 1/20 0.32
▸ HDAC6 Q9UBN7 1/20 0.32
▸ ALDH1A1 P00352 2/20 0.31
▸ KMT2A Q03164 2/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ MPI P34949 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ HSP90AA1 P07900 1/20 0.31
▸ PIK3CD O00329 1/20 0.30
▸ PIK3CA P42336 1/20 0.30
▸ PIK3CB P42338 1/20 0.30
▸ PI4KA P42356 1/20 0.30
▸ PIK3CG P48736 1/20 0.30
▸ PI4KB Q9UBF8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30611846 1.00 CYP19A1 (0.32) CYP19A1PTGER4KDM4ECYP3A4CYP2C19
SCHEMBL26105860 0.85 SLC2A1 (0.37) KDM4ECYP3A4CYP2C19HIF1AHDAC6
SCHEMBL31347169 0.85 SLC2A1 (0.37) KDM4ECYP3A4CYP2C19HIF1AHDAC6
SCHEMBL30612169 0.82 GLO1 (0.35) PTGER4ALDH1A1KMT2AMEN1HSP90AA1
SCHEMBL26107263 0.82 GLO1 (0.35) PTGER4ALDH1A1KMT2AMEN1HSP90AA1
SCHEMBL26108223 0.82 HDAC6 (0.31) HDAC6
SCHEMBL26105772 0.82 LMNA (0.33) HDAC6
SCHEMBL30612121 0.82 LMNA (0.33) HDAC6
SCHEMBL26105101 0.82 HRH4 (0.41) HDAC6ALDH1A1SMN1; SMN2
SCHEMBL30612157 0.81 HRH4 (0.31) HDAC6HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250214991-A1 BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS 2025-07-03 — — US disclosed
EP-4499629-A1 BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS Oncopia Therapeutics, Inc. D/B/A SK Life Science Labs (US) 2025-02-05 — — EP disclosed
WO-2023183919-A1 BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS ONCOPIA THERAPEUTICS, INC. D/B/A PROTEOVANT THERAPEUTICS, INC. (US) 2023-09-28 — — WO disclosed
WO-2023183919-A1 BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS ONCOPIA THERAPEUTICS, INC. D/B/A PROTEOVANT THERAPEUTICS, INC. (US) 2023-09-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214991-A1 BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS IKZF1, IKZF2, IKZF3 CYP19A1 889/4885PTGER4 4237/4885KDM4E 647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback